Rocket Pharmaceuticals (RCKT) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$1.4 billion.
- Rocket Pharmaceuticals' Retained Earnings fell 2068.97% to -$1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 billion, marking a year-over-year decrease of 2068.97%. This contributed to the annual value of -$1.2 billion for FY2024, which is 2697.04% down from last year.
- Rocket Pharmaceuticals' Retained Earnings amounted to -$1.4 billion in Q3 2025, which was down 2068.97% from -$1.4 billion recorded in Q2 2025.
- Rocket Pharmaceuticals' Retained Earnings' 5-year high stood at -$363.0 million during Q1 2021, with a 5-year trough of -$1.4 billion in Q3 2025.
- Over the past 5 years, Rocket Pharmaceuticals' median Retained Earnings value was -$837.8 million (recorded in 2023), while the average stood at -$851.3 million.
- Per our database at Business Quant, Rocket Pharmaceuticals' Retained Earnings tumbled by 7469.19% in 2021 and then crashed by 2068.97% in 2025.
- Rocket Pharmaceuticals' Retained Earnings (Quarter) stood at -$491.9 million in 2021, then plummeted by 45.1% to -$713.8 million in 2022, then crashed by 34.41% to -$959.4 million in 2023, then dropped by 26.97% to -$1.2 billion in 2024, then dropped by 14.93% to -$1.4 billion in 2025.
- Its Retained Earnings was -$1.4 billion in Q3 2025, compared to -$1.4 billion in Q2 2025 and -$1.3 billion in Q1 2025.